Plain-English translation of NCT04601116 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The MASTER study is testing whether atorvastatin, a common cholesterol-lowering drug, can help improve outcomes when added to your regular breast cancer treatment. Recent research suggests this medication may help protect against breast cancer recurrence, and this trial will study whether that benefit is real in a large group of women with early-stage, hormone-sensitive breast cancer.
While this medication is already used to lower cholesterol and prevent heart disease, scientists have noticed it may also have cancer-fighting properties. This trial exists to find out whether adding this treatment to standard breast cancer care can actually reduce the chances that the cancer will come back.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to take either the study medication or a placebo (inactive pill) once daily for 2 years, along with your standard breast cancer treatment. You'll continue all your regular cancer follow-up appointments and also fill out questionnaires about any side effects or new health issues. The study involves women across Denmark and will track how well the medication works in preventing cancer recurrence.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Denmark